对“MUC1-C是NSCLC中获得性奥希替尼耐药的常见驱动因素”的评论 - Suppr | 超能文献

Comment on "MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC".

作者信息

Haratake Naoki, Kufe Donald

机构信息

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

出版信息

J Thorac Oncol. 2024 Dec;19(12):e88-e89. doi: 10.1016/j.jtho.2024.08.016.

DOI:10.1016/j.jtho.2024.08.016

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Comment on "MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC".对“MUC1-C是NSCLC中获得性奥希替尼耐药的常见驱动因素”的评论

J Thorac Oncol. 2024 Dec;19(12):e88-e89. doi: 10.1016/j.jtho.2024.08.016.

2

MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC.MUC1-C是NSCLC中获得性奥希替尼耐药的常见驱动因素。

J Thorac Oncol. 2024 Mar;19(3):434-450. doi: 10.1016/j.jtho.2023.10.017. Epub 2023 Nov 3.

3

Comment on "MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC".对“MUC1-C是NSCLC中获得性奥希替尼耐药的常见驱动因素”的评论

J Thorac Oncol. 2024 Dec;19(12):e87-e88. doi: 10.1016/j.jtho.2024.08.012.

4

Corrigendum to 'MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC' [Journal of Thoracic Oncology 19 Issue 3 (2024) 434-450].《“MUC1-C是NSCLC中获得性奥希替尼耐药的常见驱动因素”的勘误》[《胸部肿瘤学杂志》第19卷第3期（2024年）434 - 450页]

J Thorac Oncol. 2025 Mar;20(3):399. doi: 10.1016/j.jtho.2024.12.004. Epub 2024 Dec 18.

5

Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib.针对 c-Myc 克服第三代 EGFR 酪氨酸激酶抑制剂奥希替尼治疗 EGFR 突变型 NSCLC 获得性耐药。

Cancer Res. 2021 Sep 15;81(18):4822-4834. doi: 10.1158/0008-5472.CAN-21-0556. Epub 2021 Jul 21.

6

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR-mutant NSCLC patient with acquired LMNA-NTRK1 fusion following osimertinib resistance.奥希替尼耐药后，联合使用奥希替尼再挑战和恩曲替尼对一名获得性LMNA-NTRK1融合的EGFR突变非小细胞肺癌患者的生存获益。

Respirol Case Rep. 2022 Oct 17;10(11):e01054. doi: 10.1002/rcr2.1054. eCollection 2022 Nov.

7

Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.胰岛素样生长因子-1 受体的激活赋予 EGFR T790M 突变的非小细胞肺癌对奥希替尼的获得性耐药。

Thorac Cancer. 2020 Jan;11(1):140-149. doi: 10.1111/1759-7714.13255. Epub 2019 Nov 22.

8

Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer.用于奥希替尼和塞来昔替尼共递送的纳米颗粒克服非小细胞肺癌奥希替尼获得性耐药。

Acta Biomater. 2021 Jul 15;129:258-268. doi: 10.1016/j.actbio.2021.05.018. Epub 2021 May 25.

9

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.评估 EGFR T790M 阳性肺癌患者对奥希替尼获得性耐药的耐药机制及临床意义。

JAMA Oncol. 2018 Nov 1;4(11):1527-1534. doi: 10.1001/jamaoncol.2018.2969.

10

Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC.连续液体活检揭示了EGFR驱动基因突变的动态变化，并表明EGFR扩增是NSCLC中对奥希替尼耐药的一种新机制。

Lung Cancer. 2017 Jun;108:238-241. doi: 10.1016/j.lungcan.2017.04.004. Epub 2017 Apr 10.

引用本文的文献

1

Mucin-1: a promising pan-cancer therapeutic target.粘蛋白-1：一个有前景的泛癌治疗靶点。

NPJ Precis Oncol. 2025 Jul 2;9(1):218. doi: 10.1038/s41698-025-01016-2.

2

MUC1-C dependency in drug resistant HR+/HER2- breast cancer identifies a new target for antibody-drug conjugate treatment.耐药性 HR+/HER2- 乳腺癌中 MUC1-C 的依赖性确定了抗体药物偶联物治疗的新靶点。

NPJ Breast Cancer. 2025 Apr 26;11(1):39. doi: 10.1038/s41523-025-00751-w.